Our Vision

Transforming blood test through technology innovation

As we enter the age of personalized medicine, DNA sequencing is playing an increasingly important role in determining a patient’s optimal treatment plan. Unfortunately, acquiring tumor to sequence often requires performing a tissue biopsy which can be painful, dangerous, and sometimes even impossible, as is the case with both metastatic and early stage cancer. Liquid biopsy, however, offers a viable non-invasive alternative to tissue biopsy. Not only is liquid biopsy minimally stressful for patients, but is also more comprehensive and easily performed at regular intervals. The potential applications of liquid biopsy are vast -- from targeted cancer therapy selection to real-time minimal residual disease monitoring to population-level early screening -- and we believe it will play a critical role in the future of cancer management.

核心技术

独创的专利技术


安可济创新发明的Firefly™技术是一项专门为ctDNA高通量测序研发的全新测序方案,已在美国及中国申请了多项专利保护。该技术采用“单链环化DNA滚环复制串联重复确认法”,取代国际主流的“双链DNA分子条码扩增比对确认法”,在解决了微量的循环肿瘤DNA扩增难题的同时极大地提高了检测灵敏度和特异性。

使命愿景

照亮人类攻克癌症的梦想

免疫治疗、靶向治疗等都是当今医学界更精准治疗癌症的方式,它们为人类攻克癌症提供全新的武器。液态活检通过血液进行肿瘤分子检测,是一种无创伤的探查,可以综合反映癌症的基因突变情况,比肿瘤活检更全面、更灵敏。

What We Do

Advancing technology

We make necessary technical advancement to a robust assay

Developing clinical tests

We address unmet clinical needs through partnership with research community

Partnering with the leaders

We work with experts to accelerate product development and clinical adoption

技术优势

灵敏、经济、独创

(1)灵敏:痕量DNA的转换效率高,基本消除了同类产品的样本制备中严重丢失肿瘤DNA的问题, 因此可以达到更高灵敏度。
(2)经济:在达到相同测序精度时的成本很低,相比规格接近的竞争产品可以低至1/5以下的测序成本。
(3)独创:完整的自主知识产权,完全独立的创新研发和专利申报。

Our Vision

Inventing the future of cancer diagnostics.

For each project we establish relationships with partners who we know will help us create added value for your project. As well as bringing together the public and private sectors, we make sector-overarching links to gather knowledge and to learn from each other. The way we undertake projects is based on permanently applying values that reinforce each other: sociocultural value, experimental value, building-technical value and economical value.

Heading

Our Advantages

Proprietary Technology


AccuraGen uniquely employs rolling-circle amplification to perform consensus-based concatemer error correction. The fundamental of our technology ensures a high conversion rate and minimizes the proliferations of errors.  We optimized our assay to detect a breadth of genetic alterations with a sensitivity approaching the physical limit and a specificity as much as 100x better than benchmark.

Multidisciplinary efforts

Challenging the boundaries, robust results

When our assay is approaching the phsyical limit, we take every bit of efforts to ensure a consistent and robust result. Our multidisciplinary team that spans across mathematics, statistics, computer science, clinical science, genomics, all work together to convert minute of cancer signals in the blood to actionable diagnotics-grade information with meaningful clinical economics.

Our Approach

What We Do

Experiment

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla.

Sequence

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros. Lorem ipsum dolor sit amet consectetur.

Analyze

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare.

Our Advantage

Proprietary on technology.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Successful Properties

Complex process, powerful results.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Meet Our Team

Maecenas egestas arcu quis ligula mattis placerat. Etiam imperdiet imperdiet orci. Praesent nonummy enue habitant morbi.

Learn More
管理团队

董事会

应康

董事会主席/首席执行官

崔相民

董事/德诚资本常务董事

Dan Zabrowski

德诚资本合伙人/罗氏测序和组织诊断前主管

刘江威

佳辰资本总经理

徐炜

戴勒斯资本执行合伙人

投资机构

加入我们

Latest Publications

Shanghai Yunsheng Medical Laboratory joined the Inclusive Medical Association

Shanghai Yunsheng Medical Laboratory under AccuraGen Holdings participated in the launch of the Inclusive Medical Association.

Collaborator presented AccuraGen's ctDNA-NGS kit validation at AACR

The study was conducted by Professor Jiatao Lou, director of the Chest Hospital.

Subscribe to our newsletter now.

Get our news and latest project, first.
In your mailbox. Monthly.

No spam, ever.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form